Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Cools

Showing results (91-100 of 184) with videos related to

Pageof 19
Sort By:
Scientific Reports|June 5, 2015
A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2)Romain Duval, Linh-Chi Bui, Jérémy Berthelet, et al.
Haematologica|March 7, 2008
In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemiaKim De Keersmaecker, Idoya Lahortiga, Nicole Mentens, et al.
Journal of Hematology & Oncology|August 27, 2018
The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster eye cancer modelsCarmen Vicente, Rocco Stirparo, Sofie Demeyer, et al.
Haematologica|December 21, 2014
Hedgehog pathway mutations in T-cell acute lymphoblastic leukemiaAntonis Dagklis, Daphnie Pauwels, Idoya Lahortiga, et al.
Blood|February 17, 2005
Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)Kim De Keersmaecker, Carlos Graux, Maria D Odero, et al.
Experimental Hematology|January 11, 2014
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRAIrina Sadovnik, Els Lierman, Barbara Peter, et al.
The Journal of Biological Chemistry|October 9, 2015
Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor SpecificitiesElisabeth Losdyck, Tekla Hornakova, Lorraine Springuel, et al.
Molecular Oncology|March 13, 2014
The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842VLaura A Noël, Florence A Arts, Carmen P Montano-Almendras, et al.
Gastroenterology|November 8, 2006
Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRAThomas de Raedt, Jan Cools, Maria Debiec-Rychter, et al.
Journal of Hematology & Oncology|June 25, 2021
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemiaInge Govaerts, Cristina Prieto, Charlien Vandersmissen, et al.
Pageof 19

Showing results (91-100 of 184) with videos related to

Sort By:
Pageof 19
Scientific Reports|June 5, 2015
A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2)Romain Duval, Linh-Chi Bui, Jérémy Berthelet, et al.
Haematologica|March 7, 2008
In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemiaKim De Keersmaecker, Idoya Lahortiga, Nicole Mentens, et al.
Journal of Hematology & Oncology|August 27, 2018
The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster eye cancer modelsCarmen Vicente, Rocco Stirparo, Sofie Demeyer, et al.
Haematologica|December 21, 2014
Hedgehog pathway mutations in T-cell acute lymphoblastic leukemiaAntonis Dagklis, Daphnie Pauwels, Idoya Lahortiga, et al.
Blood|February 17, 2005
Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32)Kim De Keersmaecker, Carlos Graux, Maria D Odero, et al.
Experimental Hematology|January 11, 2014
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRAIrina Sadovnik, Els Lierman, Barbara Peter, et al.
The Journal of Biological Chemistry|October 9, 2015
Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor SpecificitiesElisabeth Losdyck, Tekla Hornakova, Lorraine Springuel, et al.
Molecular Oncology|March 13, 2014
The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842VLaura A Noël, Florence A Arts, Carmen P Montano-Almendras, et al.
Gastroenterology|November 8, 2006
Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRAThomas de Raedt, Jan Cools, Maria Debiec-Rychter, et al.
Journal of Hematology & Oncology|June 25, 2021
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemiaInge Govaerts, Cristina Prieto, Charlien Vandersmissen, et al.
Pageof 19